The Drug that Changed Appetite. And Everything Around it.

Healthcare Insights

The Drug that Changed Appetite. And Everything Around it.

GLP-1s have become one of the rare medicines that stray far outside healthcare. Known now more for weight management than diabetes, they have infiltrated all manner of everyday culture.

They’re brought up in conversations about alcohol avoidance, protein goals, altered perfume preference, job interview bias and wedding dress contracts. They’re changing what people order, what they wear, what they say (or don’t say).

What makes this so significant isn’t the weight loss per se, it’s the fact GLP-1s intervene in appetite: one of the most emotional, moralised and socially visible parts of daily life. Because food isn’t just food, it’s celebration, comfort, reward, routine, culture, family, pleasure and guilt. So, when a medicine changes appetite, it changes how people participate in life.

A dinner out feels different when some people at the table are ordering less. A supermarket shop changes when the trolley is full of cottage cheese. A wardrobe needs replacing, tailoring or selling on. Even the room temperature gets renegotiated when half the room suddenly feels cold.

And it’s why…

GLP-1s create a new set of insight challenges for pharma, healthcare and consumer brands alike.

One of the biggest risks in this space is treating ‘GLP-1 users’ as one audience.

The cultural conversation can make the experience sound universal: people start treatment, manage side effects, lose weight and then work out how to maintain it. But real life is never that straightforward.

The same medication can produce very different emotional and behavioural journeys shaped by much more than weight loss alone.

Motivation matters. Some people may be driven by appearance or confidence. Others may be focused on mobility, physical wellbeing, long-term health risks or associated conditions. Some may see treatment as a turning point, a health reset or even the wedding-day solution. Others may feel conflicted, judged or unsure how to explain the change to people around them.

Stigma adds another layer of complexity. Paradoxically, weight-related stigma may be reduced, but then there’s the idea that medically supported weight loss is somehow less earned. And that matters because stigma can shape disclosure, support-seeking, confidence, adherence and how people interpret their own success.

Then there’s identity. For some people, GLP-1s may create a stronger sense of control. For others, if appetite changes, social and family life changes and if their body changes, relationships may change too.

A medicine that changes appetite can also change the story people tell about themselves.

That is why the next phase of GLP-1 insight needs to move beyond the scale.

Clinical outcomes are key, of course. But they do not tell us how people make sense of progress, how they adapt their lives, how they talk about treatment, or how they decide whether to continue, taper, stop or maintain.
For pharma and healthcare teams, these differences have implications for support, adherence risk, communication, expectation-setting and long-term engagement.

For consumer brands, they raise different but connected questions. What changes when people eat less, drink less, prioritise protein, rethink identity or navigate maintenance? What new needs, behaviours and opportunities emerge?

In both cases, the opportunity is the same: to understand the lived experience behind the outcome. That’s the thinking behind…

buzzback’s GLP-1 Experience Research Study

As part of our own ongoing thought leadership research, we are exploring how adults using GLP-1 medications for weight management experience progress, motivation, identity change and long-term treatment decisions in everyday life.

Initial analysis shows that 21% of people plan to continue using a GLP-1 long term or indefinitely. Yet decision-making does not appear to be driven by HCP guidance. Only 32% of people who changed dose did so because their HCP recommended it, while trusted medical sources rank as the eighth most influential factor in deciding next steps with a GLP-1. Cost and insurance coverage rank third.

Inspired by emerging thinking around weight-loss response phenotypes, the study looks beyond ‘users’ as one broad group and explores different responder types, shaped by reported outcomes such as rapid progress, steady change, plateauing or limited results.

Because different journeys are likely to create different needs: different support needs, different adherence risks, different messaging opportunities and different consumer behaviours.

GLP-1s may be prescribed to individuals, but their impact is playing out collectively: in families, friendship groups, workplaces, restaurants, retail, beauty, fashion and culture.

The next phase of GLP-1 insight is understanding how different people experience that change, what it reshapes in their lives and what they need next.

We’ll be sharing more from the study as the findings develop. For teams working in GLP-1s, weight management, obesity care or the related health issues these treatments touch, we’d welcome the opportunity to discuss where deeper patient understanding is needed next: from support needs and adherence risk to maintenance, long-term engagement and the realities of everyday use. Please get in touch if you’d like to explore this further.